AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8753111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Number of subjects: 26
Study 8753111 — intervention group
Group type: COMPARATOR
Intervention: 1400 micrograms/day of inhaled beclomethasone dipropionate (BDP) and bronchodilators
Number of subjects: 26
Study 8753111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP)
Number of subjects: 26
Study 8753111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 micrograms/day of inhaled beclomethasone dipropionate (BDP) and 1400 micrograms/day of BDP
Number of subjects: 26
Study 29540424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of 1000 IU fIX prothrombin complex concentrate (PCC)
Number of subjects: 310
Study 29540424 — intervention group
Group type: COMPARATOR
Intervention: Variable dose of prothrombin complex concentrate (PCC) determined by patient-specific bodyweight and international normalised ratio
Number of subjects: 310
Study 29071913 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (2 Hz/100 Hz, 6-8 mA for LI 4-PC 6, 12-18 mA for ST 36-SP 6)
Number of subjects: 58
Study 29071913 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 58
Study 24929888 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mcg (1-2 doses, administered at least 3 hours before D&E)
Number of subjects: 159
Study 24929888 — intervention group
Group type: COMPARATOR
Intervention: Laminaria inserted the day before D&E
Number of subjects: 159
Study 24929888 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 400 mcg
Number of subjects: 159
Study 24929888 — intervention group
Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 159
Study 24929888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 159
Study 22704926 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ISS (0-4 weeks schedule)
Number of subjects: 41
Study 22704926 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV-ISS (0-8 weeks schedule)
Number of subjects: 41
Study 22704926 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 41
Study 21029892 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification (OZil)
Number of subjects: 148
Study 21029892 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal phacoemulsification
Number of subjects: 148
Study 17396041 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 162
Study 17396041 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (AMB)
Number of subjects: 162
Study 15711571 — intervention group
Group type: EXPERIMENTAL
Intervention: BuCyVP (etoposide 60 mg/kg, busulfan 14 mg/kg, cyclophosphamide 120 mg/kg)
Number of subjects: 237
Study 15711571 — intervention group
Group type: COMPARATOR
Intervention: BuCy2
Number of subjects: 237
Study 15711571 — intervention group
Group type: EXPERIMENTAL
Intervention: BuCyVP
Number of subjects: 237
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting periods of 15 minutes (Group 1)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting periods of 30 minutes (Group 2)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting periods of 60 minutes (Group 3)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting periods of 120 minutes (Group 4)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (15 min rest)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (30 min rest)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (60 min rest)
Number of subjects: 52
Study 12422158 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (120 min rest)
Number of subjects: 52
Study 9609264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin 500 mg intra-operatively
Number of subjects: 79
Study 9609264 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 79
Study 8535492 — intervention group
Group type: EXPERIMENTAL
Intervention: Grinder exposure
Number of subjects: 0
Study 8535492 — intervention group
Group type: EXPERIMENTAL
Intervention: Chipping hammer exposure
Number of subjects: 0
Study 2797635 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring
Number of subjects: 0
Study 2797635 — intervention group
Group type: COMPARATOR
Intervention: Periodic auscultation
Number of subjects: 0
Study 30769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (3 mg per day, given b.i.d., 2 mg h.s. and 1 mg a.m. for 4 weeks)
Number of subjects: 48
Study 30769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31256870 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Pump Activator (MPA) device
Number of subjects: 118
Study 31256870 — intervention group
Group type: COMPARATOR
Intervention: TED + IPC
Number of subjects: 118
Study 27808527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based eating disorder program
Number of subjects: 47
Study 27808527 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 47
Study 25138265 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day vitamin D3
Number of subjects: 26
Study 25138265 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 26
Study 23145957 — intervention group
Group type: EXPERIMENTAL
Intervention: Advise-coitus
Number of subjects: 1150
Study 21478245 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 51
Study 21478245 — intervention group
Group type: COMPARATOR
Intervention: Non-platelet-rich plasma (non-PRP)
Number of subjects: 51
Study 19340512 — intervention group
Group type: EXPERIMENTAL
Intervention: NEM(R) 500 mg daily for 8 weeks
Number of subjects: 67
Study 19340512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16966479 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 145
Study 12718461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical guidelines plus postal feedback on prescribing patterns for antibiotics
Number of subjects: 299
Study 12718461 — intervention group
Group type: COMPARATOR
Intervention: Clinical guidelines only
Number of subjects: 299
Study 10930561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (5000 lux) and caffeine (100 mg)
Number of subjects: 62
Study 10930561 — intervention group
Group type: COMPARATOR
Intervention: Bright light (5000 lux)
Number of subjects: 62
Study 10930561 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (100 mg)
Number of subjects: 62
Study 10930561 — intervention group
Group type: COMPARATOR
Intervention: Dim light placebo
Number of subjects: 62
Study 10930561 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light exposure
Number of subjects: 62
Study 9382473 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage-targeted glucocerebrosidase (Ceredase) infusions, dosage ranged from 120 to 480 U/kg of body weight/month
Number of subjects: 5
Study 9382473 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage-targeted glucocerebrosidase (Ceredase) infusions
Number of subjects: 5
Study 8266769 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms tds) by subcutaneous injection for 12 days
Number of subjects: 19
Study 8266769 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 12 days
Number of subjects: 19
Study 3534901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyritinol (200 mg, three times daily)
Number of subjects: 120
Study 3534901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31152463 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone crisis counseling
Number of subjects: 234
Study 29424030 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-ESD
Number of subjects: 84
Study 29424030 — intervention group
Group type: COMPARATOR
Intervention: Conventional-ESD
Number of subjects: 84
Study 27408622 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded patient self-reported outcome
Number of subjects: 240
Study 27408622 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded assessment of digital photographs
Number of subjects: 240
Study 27408622 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded outcome assessment at the site
Number of subjects: 240
Study 24726004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanochemical endovenous ablation (MOCA)
Number of subjects: 460
Study 24726004 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 460
Study 23026303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunsimgi-eum (BSGE)
Number of subjects: 0
Study 23026303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (controlled medication)
Number of subjects: 0
Study 20831455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 146
Study 20831455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 18756848 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ridge pattern characteristics
Number of subjects: 390
Study 18756848 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison of digital ridge patterns
Number of subjects: 390
Study 18756848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern Intensity Index
Number of subjects: 390
Study 18756848 — intervention group
Group type: EXPERIMENTAL
Intervention: Total finger ridge count and a-b ridge count
Number of subjects: 390
Study 16230523 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (80 mg)
Number of subjects: 159
Study 16230523 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg)
Number of subjects: 159
Study 16230523 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 159
Study 11850097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (up to 300 mg bid)
Number of subjects: 135
Study 11850097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 10726436 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity, short duration with glucose in milk (HS & GM)
Number of subjects: 10
Study 10726436 — intervention group
Group type: COMPARATOR
Intervention: High intensity, short duration without glucose in milk (HS & NGM)
Number of subjects: 10
Study 10726436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity, long duration with glucose in milk (LL & GM)
Number of subjects: 10
Study 10726436 — intervention group
Group type: COMPARATOR
Intervention: Low intensity, long duration without glucose in milk (LL & NGM)
Number of subjects: 10
Study 10726436 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercises
Number of subjects: 10
Study 7785756 — intervention group
Group type: EXPERIMENTAL
Intervention: DAR Hygrobac HME
Number of subjects: 25
Study 7785756 — intervention group
Group type: EXPERIMENTAL
Intervention: Gibeck Humid Vent 2P HME
Number of subjects: 25
Study 7785756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall BB 22‐15 T HME
Number of subjects: 25
Study 7785756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pall BB 100 HME
Number of subjects: 25
Study 2331550 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural procedures
Number of subjects: 1
Study 6999827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketocaine compresses (10% ethanol solution)
Number of subjects: 50
Study 6999827 — intervention group
Group type: COMPARATOR
Intervention: Saline compresses (placebo)
Number of subjects: 50
Study 30895460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua cycling (AC)
Number of subjects: 20
Study 30895460 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (P)
Number of subjects: 20
Study 28696415 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (N = 186)
Number of subjects: 391
Study 28696415 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 205)
Number of subjects: 391
Study 30228572 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 0
Study 30228572 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 0
Study 26408290 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual assault risk reduction condition
Number of subjects: 207
Study 26408290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use reduction condition
Number of subjects: 207
Study 26408290 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sexual assault risk and alcohol use reduction condition
Number of subjects: 207
Study 26408290 — intervention group
Group type: COMPARATOR
Intervention: Full assessment only control condition
Number of subjects: 207
Study 26408290 — intervention group
Group type: COMPARATOR
Intervention: Minimal assessment only condition
Number of subjects: 207
Study 23212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic imatinib (arm A)
Number of subjects: 55
Study 23212150 — intervention group
Group type: COMPARATOR
Intervention: MRD-triggered imatinib (arm B)
Number of subjects: 55
Study 23212150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 55
Study 21606634 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 114
Study 21606634 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced coughing
Number of subjects: 114
Study 21606634 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study 19092037 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults adapting to 1/f noise structure of target-force waveform
Number of subjects: 0
Study 19092037 — intervention group
Group type: COMPARATOR
Intervention: Young adults adapting to 1/f noise structure of target-force waveform
Number of subjects: 0
Study 16785755 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 27
Study 16785755 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 12656658 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200 microg plus L-thyroxine (LT(4))
Number of subjects: 65
Study 12656658 — intervention group
Group type: COMPARATOR
Intervention: L-thyroxine (LT(4)) plus placebo
Number of subjects: 65
Study 11152061 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal dietary supplement containing 10 mg of caffeine and 5 mg of ephedrine
Number of subjects: 10
Study 11152061 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study 9322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 114
Study 9322173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber floor mats
Number of subjects: 114
Study 9322173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 8446844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg twice daily for 7 days
Number of subjects: 30
Study 8446844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen, 2 mg twice daily for 24 hours before indomethacin administration
Number of subjects: 30
Study 8446844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3946946 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxepin
Number of subjects: 7
Study 3946946 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg doxepin
Number of subjects: 7
Study 3946946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30946987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 30946987 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 29878870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2WALK (sitting with 2-min light-intensity walking breaks every 30 min)
Number of subjects: 15
Study 29878870 — intervention group
Group type: COMPARATOR
Intervention: SIT (uninterrupted sitting)
Number of subjects: 15
Study 29878870 — intervention group
Group type: EXPERIMENTAL
Intervention: 8WALK (sitting with 8-min light-intensity walking breaks every 2 h)
Number of subjects: 15
Study 29878870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2WALK
Number of subjects: 15
Study 27120106 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 0.3 g/dl GOS (OM55N)
Number of subjects: 35
Study 27120106 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 35
Study 1428301 — intervention group
Group type: COMPARATOR
Intervention: Midecamycin acetate
Number of subjects: 12
Study 1428301 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 12
Study 1428301 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin
Number of subjects: 12
Study 22797673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin concentrations (1-tertile increase)
Number of subjects: 524
Study 22797673 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tertiles of ferritin
Number of subjects: 524
Study 21129229 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 20
Study 21129229 — intervention group
Group type: COMPARATOR
Intervention: UF-heparin
Number of subjects: 20
Study 18185145 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular grid laser photocoagulation (MGLP)
Number of subjects: 31
Study 18185145 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 31
Study 18185145 — intervention group
Group type: EXPERIMENTAL
Intervention: MGLP
Number of subjects: 31
Study 18185145 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study 16395369 — intervention group
Group type: COMPARATOR
Intervention: MOD inlay preparation (Group A)
Number of subjects: 80
Study 16395369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PCR (Group B)
Number of subjects: 80
Study 16395369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PCR (Group C)
Number of subjects: 80
Study 16395369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PCR (Group D)
Number of subjects: 80
Study 16395369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PCR (Group E)
Number of subjects: 80
Study 14595300 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for Forrest Ib‐IIb ulcers with positive Doppler signal
Number of subjects: 80
Study 14595300 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for Forrest IIc‐III ulcers with positive Doppler signal
Number of subjects: 80
Study 14595300 — intervention group
Group type: COMPARATOR
Intervention: No therapy for Forrest IIc‐III ulcers with positive Doppler signal
Number of subjects: 80
Study 14595300 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler signal present after endoscopic therapy
Number of subjects: 80
Study 10584158 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled trials (PCTs)
Number of subjects: 8
Study 10584158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonplacebo-controlled trials (NPCTs)
Number of subjects: 8
Study 8707096 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU injections (group A)
Number of subjects: 141
Study 8707096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MU injections (group B)
Number of subjects: 141
Study 8707096 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the dose of interferon in group B
Number of subjects: 141
Study 8707096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MU injections (group B) with normal ALT
Number of subjects: 141
Study 2735516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 'booster' (n = 10)
Number of subjects: 20
Study 2735516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study 1106229 — intervention group
Group type: EXPERIMENTAL
Intervention: DFD-Py
Number of subjects: 659
Study 1106229 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS-Py
Number of subjects: 659
Study 1106229 — intervention group
Group type: EXPERIMENTAL
Intervention: DFD alone
Number of subjects: 659
Study 1106229 — intervention group
Group type: COMPARATOR
Intervention: Py alone
Number of subjects: 659
Study 1106229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 30973053 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion threshold
Number of subjects: 181
Study 30973053 — intervention group
Group type: COMPARATOR
Intervention: GOS and GOS-E
Number of subjects: 181
Study 30973053 — intervention group
Group type: COMPARATOR
Intervention: Ordinal logistic regression or sliding dichotomy method
Number of subjects: 181
Study 28160772 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 53
Study 28160772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 26579625 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive jump training
Number of subjects: 21
Study 26579625 — intervention group
Group type: COMPARATOR
Intervention: Non-specific training (Control)
Number of subjects: 21
Study 23287787 — intervention group
Group type: EXPERIMENTAL
Intervention: Top 2 tHcy quartiles (Q3 and Q4)
Number of subjects: 1327
Study 21215382 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth lifestyle counseling (active control plus 6 weekly 1‐hour teleconferenced sessions to groups of 4 to 8 subjects)
Number of subjects: 680
Study 21215382 — intervention group
Group type: COMPARATOR
Intervention: Active control (risk factor feedback, brief advice, handouts)
Number of subjects: 680
Study 21215382 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth lifestyle counseling
Number of subjects: 680
Study 21215382 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 680
Study 21215382 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Telehealth and Active control)
Number of subjects: 680
Study 18553130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 500
Study 18553130 — intervention group
Group type: COMPARATOR
Intervention: Patients without depression
Number of subjects: 500
Study 23027490 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation
Number of subjects: 108